Search

Mitochondria-enriched Genetically Engineered Cells and Uses Thereof

The USPTO granted Patent No. US12605410B2 to Minovia Therapeutics Ltd. covering pharmaceutical compositions of mitochondrially-enriched genetically engineered T cells and methods of using such cells to treat diseases and disorders. The patent, with 18 claims, was filed on March 30, 2021. This IP grant gives Minovia enforceable rights to its cell engineering technology through the patent term.